Xarelto
Directly inhibits factor Xa to interrupt both intrinsic and extrinsic coagulation pathways, reducing thrombin generation and preventing formation and extension of blood clots.
- Category
- Blood Thinners
- Active ingredient
- Rivaroxaban
- Route
- Oral use
- Form
- Film-coated tablet; Granules for oral suspension
- Strengths
- 15mg
You will receive a quality generic equivalent of Xarelto, depending on stock.
Prescription and consultation requirements for Xarelto vary by destination and are determined by the fulfilment partner.
Xarelto details
- Conditions
- Prevention of Atherothrombotic Events in Adult Patients After An Acute Coronary Syndrome with Elevated Cardiac Biomarkers, Co-administered with Acetylsalicylic Acid Alone or with Clopidogrel or Ticlopidine · Prevention of Atherothrombotic Events in Adult Patients with Coronary Artery Disease or Symptomatic Peripheral Artery Disease At High Risk of Ischaemic Events, Co-administered with Acetylsalicylic Acid · Prevention of Venous Thromboembolism in Adult Patients Undergoing Elective Hip or Knee Replacement Surgery · Treatment of Deep Vein Thrombosis and Pulmonary Embolism and Prevention of Recurrent Dvt and PE in Adults · Prevention of Stroke and Systemic Embolism in Adult Patients with Non-valvular Atrial Fibrillation with One or More Risk Factors · Treatment of Venous Thromboembolism and Prevention of Vte Recurrence in Children and Adolescents Aged Less Than 18 Years
- Therapeutic class
- Antithrombotic agents
- Pharmacological class
- Direct factor Xa inhibitor
- Minor side effects
- haemorrhage; anaemia; dizziness; headache; nausea; constipation; diarrhoea
- Dosage forms
- Film-coated tablet; Granules for oral suspension
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Bayer AG
- Storage instructions
- This medicinal product does not require any special storage conditions.
Contraindications
hypersensitivity to rivaroxaban or any excipients; clinically significant active bleeding; lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except under specific circumstances; hepatic disease associated with coagulopathy and clinically relevant bleeding risk; pregnancy and breast-feeding
Precautions and warnings
increased risk of bleeding; careful observation for signs of bleeding recommended; not recommended in patients with severe renal impairment unless benefit outweighs risk; caution in patients with moderate renal impairment receiving concomitant medicines that increase rivaroxaban plasma concentrations; caution in patients with an increased bleeding risk; spinal or epidural anaesthesia carries risk of spinal or epidural haematoma; not recommended in patients with prosthetic heart valves; not recommended for acute coronary syndrome patients with prior stroke or transient ischaemic attack; patients should be provided with a patient alert card
Moderate side effects
tachycardia; syncope; pruritus; rash; oedema peripheral; pyrexia; transaminases increased
Serious side effects
intracranial haemorrhage, requires immediate medical attention; gastrointestinal haemorrhage, requires immediate medical attention; retroperitoneal haemorrhage, requires immediate medical attention; spinal or epidural haematoma, requires immediate medical attention; haemorrhagic shock, requires immediate medical attention; anaphylactic reaction, requires immediate medical attention
Patient summary
Directly inhibits factor Xa to interrupt both intrinsic and extrinsic coagulation pathways, reducing thrombin generation and preventing formation and extension of blood clots.
Mechanism of action
Xarelto contains rivaroxaban, a medicine known as a direct oral anticoagulant. It works by blocking a substance in the blood called factor Xa, which is essential for blood clotting. By reducing factor Xa activity, Xarelto helps prevent harmful blood clots from forming in veins and arteries and treats existing clots. It is used to prevent stroke in people with irregular heartbeat (atrial fibrillation), to treat and prevent deep vein clots and lung clots, and to prevent clots after hip or knee replacement surgery.
Drug interactions
other anticoagulants; NSAIDs; acetylsalicylic acid; antiplatelet agents; CYP3A4 and P-gp inhibitors; selective serotonin reuptake inhibitors; serotonin norepinephrine reuptake inhibitors
Age restrictions
Not recommended for children aged less than 18 years except for treatment of VTE and prevention of VTE recurrence in children weighing from 30 kg.
Pregnancy and breastfeeding
Contraindicated during pregnancy. Animal studies have shown reproductive toxicity. Women of childbearing potential should avoid becoming pregnant during treatment.
What you will receive
Xarelto is the originator brand name, made by Bayer AG. We use it to identify the medicine and are not affiliated with Bayer AG.
- The fulfilment partner confirms whether the exact brand or an equivalent containing Rivaroxaban is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.